PRIX GALIEN USA 2022
GALIEN FORUM
THURSDAY OCTOBER 27

Alexandria Center for Life Science
AQEMIA

Aqemia is a pharmatech company generating one of the world’s fastest-growing drug discovery pipeline. Our mission is to design innovative drug candidates for dozens of critical diseases. Our differentiation lies in our unique quantum and statistical mechanics algorithms that comes from 10 years of academic research in Oxford, Cambridge, and CNRS. This breakthrough technology predicts the efficiency of molecules 10,000 times faster and more accurately than what exists today on the market, from the nature and position of atoms. It fuels a generative artificial intelligence to design novel drug candidates with better chances of success. The velocity and precision of our digital platform allows us to scale drug discovery projects like technology projects.

We are developing a massive pipeline of wholly-owned drug discovery projects, in order to generate dozens of up to $1B-worth Biotechs.

Aqemia was created in 2019, and in only 3 years the company already achieved key milestones:
- Built a team of 45 top-tier people at the crossroads of Chemistry and Machine Learning.
- Collaborating with several top Big Pharmas such as Sanofi, Servier and Janssen with 2m$ in revenues, and renewed the two first contracts after promising results.
- Started multiple internal pipeline projects since September 2021, with early good results to build on.
- Fundraised $12m with Eurazeo (largest European investment fund) and Elaia Partners (French first deeptech VC fund).

AURION BIOTECH

Based in Seattle, Boston and Tokyo, Aurion Biotech is a clinical-stage biotech company. Our mission is to restore vision to millions of patients with our life-changing regenerative therapies. Our first candidate is for the treatment of corneal edema secondary to endothelial dysfunction, and is one of the first clinically validated cell therapies for corneal care. Healthy cells from a donor cornea are cultured in a novel, multi-step, proprietary and patented process. Cells manufactured from a single donor can treat more than 100 recipient eyes. In clinical trials in Japan, patients have experienced significant and durable improvements in key measures of corneal health: visual acuity, corneal endothelial cell density and central corneal thickness. The Aurion Biotech team is preparing for clinical trials in the U.S. To learn more about Aurion Biotech, visit www.aurionbiotech.com
Today’s limits of precision oncology remain strong and current therapies lacks efficacy due to the tumor plasticity: CANCER IS A MOVING TARGET. Brenus Pharma develops first-in-class allogeneic cell immune therapies through a proprietary discovery platform STC (Stimulated Tumor Cells) to anticipate tumor resistance and increase persistence of the immune response with 3 principles:

- **REPRESENTATIVITY**: The process starts with a datamining-based selection of the most representative tumor cells of a specific cancer type from allogeneic tumor bank. STC1010, our first candidate targets metastatic colorectal cancer.
- **ANTIGENICITY**: The cells are exposed to conditions mimicking actions of standard of cares. These stimulations induce the overexpression of a large panel of neoantigens linked to mechanisms of resistance of patient’s tumor cells.
- **IMMUNOGENICITY**: Enabling these neoantigens to be recognized by the immune system via an immunoegenic tagging (DNFB haptenization). The cells are then inactivated, becoming non-proliferative shelves of tumor specific antigens which can be safely administered to patients to educate the immune system to target resistant tumor cells.

The STC therapy is the first complete off-the shelf approach targeting over 200 cancer related antigens:

- Allowing to maintain cost, production time and supply
- Provide the treatment to an important population

To date, our preclinical package and CMC has been reviewed by regulators, we initiate scale-up of GMP manufacturing and started our Clinical Trial Approval track for 2023. We are leveraging our platform IP (EU5, JP and US granted) to speed up generation of new candidates and address new indications.

**CTIBIOTECH™** produces biological assays and predictive systems on human tissues to develop long-term strategies for healthcare using tissue engineering and 3D-Bioprinting. 3D-Bioprinting uses additive manufacturing technologies to assemble human cells to biomaterials and nutrients in a precise and organized architecture with high level of reproducibility. CTIBIOTECH™ pioneered functional human tissue production with validated 3D-Bioprinting protocols for medium and high throughput screening on 100 to 200 identical human tissue models per donor): e.g. Immunized and Vascularized skin, cancer models (pancreas, colorectal, breast, ovary, liver, lung etc), liver models for toxicology assays. The development of personalized cancer medicine requires the production of reliable, robust, reproducible, predictive human biological models in sufficient quantity to accelerate the development of drug candidates for new chemotherapies and immunotherapies. CTIBIOTECH™ developed an industrial process for standardized production of bioprinted human tumor models that, post-production, can further self-renew and self-organize whilst retaining the characteristics of the biological structure and function of the patient’s tumor. Each patient’s tumor is processed from a consented donor in order to isolate the different cell types of interest (cancer cells, cancer-associated fibroblasts, immune cells, normal adjacent tissue-cells, endothelial cells etc), multiply their number via proprietary cell culture procedure, and then create specific “biocartridges” containing each cell type and its associated “bioink” for 3D-bioprinting.

CTITherapy™ OncoTest is a fully validated industrial process for the standardized bioproduction of hundreds of copies of human “microtumors” from a given cancer patient using 3D-Bioprinting to validate targeted-, combined-, precision and/or personalized medicine against cancer.
CURIE THERAPEUTICS

https://curietherapeutics.com/

Everyone has been directly or indirectly been affected by cancer. While the treatment of hematological malignancies has been transformed, solid tumors remain difficult to treat. Curie Therapeutics, named after the scientific unit of radiation and the first female Nobel prize winner, Marie Curie, is a start-up aiming to harness the destructive efficiency of radiation, delivered by molecules targeting proteins found uniquely in the tumor to kill tumor cells. Curie Therapeutics was founded to bring together cutting-edge peptide drug discovery with recent developments in radiochemistry. We have developed libraries of peptide molecules with enhanced permeability features that allow deep, homogeneous penetration of solid tumors into regions not accessible to other modalities. Curie rationally engineers the scaffold structure of the peptides, the physicochemical properties and location-specific docking of radioactive payloads.

Curie was conceived as a “fully integrated” company that can manufacture its own drugs and take them to “bedside”. Our specialized manufacturing leadership bring a collective 50+ years of radiopharmaceutical experience, with multiple successful diagnostic and therapeutic approvals. Our wholly owned GMP drug product manufacturing facility will expedite translation into clinical trials.

Curie’s mission is “to revolutionize the use of radiopharmaceuticals in cancer.” Our pipeline is focused on first-in-class approaches to solid tumors such as small cell lung cancer, head & neck cancer, breast and bladder cancer. Marie Curie once said; “One never notices what has been done; one can only see what remains to be done.” At Curie Therapeutics we are all on an uncompromising mission to greatly improve cancer treatments.

DEKA BIOSCIENCES

https://www.dekabiosciences.com/

Deka Biosciences is a biotech company focused on the development of novel cytokine therapies to treat cancer and inflammatory diseases such as Crohn’s, psoriasis, rheumatoid arthritis and sepsis. The company is led by entrepreneur Dr. John Mumm, who is backed by a team of experienced biopharma and CDMO innovators with expertise in drug discovery, product development, characterization and testing. Deka has developed disease specific Diakines™ that maximize patient benefits through improved pharmacokinetics / pharmacodynamics (PK/PD) function via targeted delivery of dual and complimentary cytokines to affected tissues or cells. Using precision medicine, Deka will maximize the impact of its Diakines™ by building targeted therapies for every patient.
DIACURATE is on its way to become a key player in oncology. In this undoubtedly competitive field, the French biotech company develops unique and promisingly differentiated assets rooted in expert cell biology concepts:

- **DIACC3010** is an oral brain-penetrant optimized inhibitor of S6 kinase, a master regulator of cancer cell proliferation associated with poor prognosis and broad treatment resistance. DIACC3010 phase 1 trial in advanced solid tumors established its favorable safety profile as single agent as well as in combination with various standards-of-care. Encouraging signs of clinical activity in genetically defined subgroups of refractory cancers were uncovered. Phase 2 clinical program in multiple cancer indications, including ER+ metastatic breast cancer, will be launched in 2022.

- **DIACC2010** is a selective inhibitor of KIF20A kinesin, a novel oncology target that controls both mitosis and Golgi apparatus vital functions and is overexpressed in rapidly dividing tumor cells. DIACC2010 has demonstrated potent preclinical efficacy in multiple aggressive and resistant tumor models, opening opportunities for multiple developments. As stand-alone, DIACC2010 will be developed for the treatment of Acute Myeloid Leukemia. In addition, DIACC2010 chemistry has shown suitability for conjugation to an antibody and is a potential new payload for antibody-drug conjugates (ADC). Proof of concept in animal models will be achieved by early 2023.

Diaccurate has forged alliances with leaders in academia and industry, including Pasteur Institute, Paoli-Calmettes Institute and now Merck KGaA. It relies on a high-level management team led by Dr. Dominique Bridon and world-class Scientific and Medical Advisory Boards.

https://www.diacurate.com/
**GENOSCIENCE PHARMA**

Genoscience Pharma was founded in 2001 by Pr Philippe Halfon, a world-renowned medical expert on viral diseases, especially on Human Immunodeficient Virus (HIV) and Hepatitis C Virus (HCV). The company was initially focused on the development of anti-HCV agents. Two protease inhibitors were thus developed and out-licensed to BioLineRX.

A new scientific direction was taken in 2012 after the discovery of a new chemical family: autophagy inhibitors. Following promising preliminary in vitro and in vivo results from these small molecules, including against cancer stem cells, Genoscience Pharma has decided to take the opportunity to make the difference in oncology, especially in cancers where medical needs are still unmet. Now, Genoscience Pharma is a clinical stage biopharmaceutical company focused on translating novel scientific insights into medicines for patients with cancer. Its lead candidate GNS561 is a phase 2 ready best-in-class drug candidate, tackling cancer cells through autophagy modulation.

https://www.genosciencepharma.com/

**HUMMINGBIRD BIOSCIENCE**

Hummingbird Bioscience is a data-driven precision biotherapeutics team discovering and developing transformative biologic medicines for hard-to-treat diseases. The Hummingbird Bioscience model combines computational and systems biology, and wet lab drug discovery in a multi-disciplinary, collaborative environment spanning initial discovery through clinical development. We harness this integrated approach across target identification and patient selection, enabling our team to increase the efficiency of translating novel scientific insights while reducing the inherent risk in drug discovery and development.

At Hummingbird Bioscience, our commitment to rigorous science, teamwork, and intellectual integrity underpin our passion to accelerate the journey of new drugs from concept to clinic.

https://hummingbirdbioscience.com/

**MAIA BIOTECHNOLOGY**

MAIA Biotechnology, Inc. is a targeted therapy, immune-oncology company, focused on development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. THIO, our lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Our THIO program drives our development pipeline of second-generation telomere targeting agents.

https://maibiotech.com/
Parthenon Therapeutics is a development stage precision oncology biotech advancing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME).

Many cancers use the TME to build barriers that shield the tumor from being attacked by the immune system resulting in immune-excluded tumors and associated poor survival. These tumors are characterized by the presence of immune cells that are unable to penetrate the tumor core to mount an immunological attack due to distinct defense mechanisms that have largely been overlooked to date, and also comprise a large number of immunotherapy non-responsive tumors.

Parthenon’s pipeline and drug discovery platform unify insights derived from human tumor biospecimens, experimental biology, and cutting-edge computationally intensive approaches to identify biological nodes that can be leveraged therapeutically to strike at cancers in an unprecedented way. One approach, PRTH-101, is a first-in-class therapeutic monoclonal antibody targeting the key collagen receptor (DDR1) involved in the formation of mechanical barriers underpinning immune exclusion within a tumor.

By specifically disrupting the formation of higher order collagen structures that form a mechanical barrier around the tumor, treatment with PRTH-101 as a single agent allows immune cells to infiltrate and destroy the tumor. PRTH-101 is completing IND-enabling studies, and is expected to begin clinical trials in cancer patients in the first half of 2023.

Based on rigorous, groundbreaking research, Parthenon is building a pipeline of drug candidates to treat the right patients at the right time to achieve significant and durable responses and transform the Standard of Care.
**RECODE THERAPEUTICS**

ReCode Therapeutics is a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation genetic medicines technology that enables precise delivery to target organs and cells beyond the liver. Described by Nature as one of the “Seven Technologies to Watch in 2022,” ReCode’s SORT LNP platform is an innovation beyond the lipid delivery system used by the mRNA COVID vaccines and novel RNA and gene correction therapeutics.

ReCode’s SORT LNPs are engineered with a biochemically distinct fifth lipid to help the body “sort” and direct the LNPs to other targeted organs such as the lung and spleen with the ability to bypass the liver, if desired. ReCode’s SORT LNP platform is further distinguished by its versatility in both mode of administration and the diversity of genetic cargo that can be delivered. Together, these qualities offer vast opportunities to address a wide range of unmet medical needs through a precision medicine approach that delivers the right medicine to the right organs and cells using the optimal mode of administration.

ReCode’s pipeline of disease-modifying mRNA and gene correction therapeutics include its lead programs focused on primary ciliary dyskinesia and cystic fibrosis. The company plans to expand its pipeline of genetic medicines to include central nervous system, lung, liver, and oncology indications.

For more information, visit www.recodetx.com and follow us on Twitter @ReCodeTx and LinkedIn.

---

**SMART IMMUNE**

Smart Immune is a clinical-stage biotechnology company developing ProTcell™, a thymus-empowered cell therapy platform to fully and rapidly re-arm the immune system, enabling next-generation allogeneic T-cell therapies for all. The company was founded in 2017 to help patients with life-threatening diseases such as high-risk blood cancers and primary immunodeficiencies.

Smart Immune’s ProTcell™ platform, which is already in Phase I/II clinical trials, enables the recovery of a complete immune repertoire in immuno-compromised patients by introducing potent, allogeneic T-cell progenitors which are then differentiated by the thymus into fully functional T-cells – an 'off the shelf' T-cell medicine.

Smart Immune’s partners include Memorial Sloan Kettering in New York and Greater Paris University Hospitals (AP-HP). The company is headquartered in Paris Biotech Santé, 29 rue du Faubourg St Jacques, France.
ACORAI

Acorai is developing the next heart failure vital sign tool to improve standard of care for heart failure (HF) patients. Our device, The Acorai Heart Monitor, is one of its kind and can non-invasively monitor the intracardiac pressures (the most important vital signs when it comes to managing HF patients). Our patented and clinically validated solution is a handheld medical device built on novel machine learning insights into pressure & flow dynamics in acoustic, vibratory and waveform data. Most importantly, we have a unique value proposition that appeals to both healthcare professionals and payors which further strengthens our potential. Acorai has the potential to become the standard of monitoring and management for all heart failure patients worldwide. With the versatile distribution platform, the company can expand the product offering to include multiple HF-related diseases, while at the same time expanding into other areas of the healthcare system.

VISION: To ensure optimal care for HF patients globally.
MISSION: To create a product that changes people’s lives. To be part of the transformation of the medical industry towards non-invasive, cost-effective, and more inclusive technologies, thereby increasing the reach of care.

Acorai’s value proposition is to help healthcare professionals improve quality and efficiency of care in the heart failure (HF) patient workflow and reduce costs by reducing heart failure readmission penalties and length of stay. With a team with more than 50 years of industry experience, we can help heart failure patients live longer, healthier, and less uncertain lives.

DESSINTEY

Dessintey develops intensive rehabilitation technologies to help patients regain autonomy faster.

Our first device IVS3 (Intensive Visual Simulation) is dedicated to upper limb rehabilitation for patients suffering from stroke (severe to moderate).

IVS3 is a unique technology which stimulates action planning and promotes « motor priming »

It was developed in partnership with Pr.Pascal GIRAUX, co-founder and head of Saint Etienne Hospital Rehab Department in France. For many patients, the first phase of action planning can be altered or non-existent. They often lose body perception, imagination of movement. And at the end, the ability to create an effective motor command.

The IVS3 system is based on the fundamental principles of visuomotor simulation training approaches which have a strong level of evidence. It generates model of actions (visual & sensorimotor representations) which will support the patient to imagine, to plan and at the end to perform a movement.

IVS3 replaces the image of the paralysed arm with a positive image of movement performed by the healthy arm (previously recorded). By reinstating coherence between what the patient intends to do and the sensations he perceives, this approach prompts relearning. Its technological platform integrates intelligent algorithm-based therapy assistance to facilitate the clinician’s day-to-day practice. It suggests tips to the therapists according to the various kinds of pathologies when preparing the sessions. Our device has been CE marked since mid 2018 and more than 150 rehab centers have placed their trust in Dessintey in France, Germany, Switzerland, Spain, Italy, Belgium, Northern Countries, Korea…
**Dynocardia**

Dynocardia, a Massachusetts Institute of Technology and Tufts University School of Medicine spinoff, is addressing a 100-year-old challenge and an unmet need for accurate and continuous non-invasive blood pressure (BP).

ViTrack™ is the first cuff-less, wrist-wearable technology that includes a proprietary optomechanical sensor and a new method for accurate and continuous BP, respiratory and advanced heart parameters. ViTrack technology is fundamentally different from all existing BP devices. ViTrack, based on pressure-dependent skin displacement, is the first to measure beat-to-beat systolic and diastolic BPs directly with the accuracy of invasive arterial pressure without external calibration, irrespective of subject movement or wrist position relative to the heart (hydrostatic pressure change).

ViTrack, with accurate and continuous data, enables predictive monitoring to benefit millions of critically ill hospital patients. In 1.5 billion with hypertension globally, ViTrack’s 24-hr BP parameters, BP variability, and nighttime BP will reduce the 30% misdiagnosis rate, improve the 40% BP control rate, and facilitate better risk prediction to prevent stroke, heart attacks, and other complications. ViTrack will impact other conditions that benefit from good BP control, such as sleep apnea and heart and kidney failure. In addition, ViTrack will provide fundamentally new real-world data for cardiovascular disease prevention (wellness).

Dynocardia is laying the groundwork for entry into the hospital critical care sub-segment and will eventually deploy the technology into various care settings, including the consumer market. Over time, by integrating data across care settings, Dynocardia will produce crucial and unique predictive insights that will benefit the entire healthcare ecosystem.

**EpiLAB**

Tuberculosis is a devastating pandemic, the disease claimed 1.5 million victims in 2018. According to the WHO, in 2018, 10 million people fell ill with tuberculosis among which 3 million are undetected, thus increasing contamination and death. 80% of the cases are located in developing countries and the tests deployed in these regions require medical facilities and qualifications, which increase the difficulty to bridge the diagnosis gap. There is an urgent need for innovative ways to diagnose tuberculosis and fight this deadliest disease, surpassing HIV and malaria. EpiLab tuberculosis diagnosis technology is portable, simple to use, precise and robust. The EpiLAB diagnosis is a pre-screening test, operated prior to more precise and expensive tests, it aims at reducing the diagnosis gap of the 3 million undetected cases each year.

The test matches the World Health Organization requirements for innovation in TB diagnosis technology:
- portable & simple to use: no medical facility or qualification are required;
- precise & robust: precision exceeding most of the diagnosis present in the market (see below);
- quick results: the diagnosis is produced in 2 hours, the results are consolidated and encrypted in a cloud which will foster patient traceability and treatment;
- affordable: the target price is lower than 5$.

The EpiLAB’s diagnosis kit leverages a patent from INRAE and Université de Bourgogne. It consists of an in vitro diagnostic kit that quickly detects the presence or absence of mycobacteria in respiratory samples. The innovation is a method based on the electrochemical detection of the enzymatic activity of a specific antigen in the presence of a substrate and a co-substrate.
<table>
<thead>
<tr>
<th><strong>I.CERAM</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Founded in 2005 in Limoges, France, I.Ceram designs, manufactures and markets innovative surgical implants for the human body, and more particularly the skeleton. I.Ceram, certified ISO 13485 and ISO 14001, benefits from the knowledge of its customers, but also from a capacity to create solutions allowing the reliability of surgical techniques for the benefit of patients. The creation of the scientific committee has greatly accelerated the development of porous alumina bioceramics. The development of new technologies linking ceramics and surgery has been the driving force of I.Ceram since 2014. I.Ceram has its own industrial tool in Limoges, has its own ceramic, chemical and biological laboratories. The company’s research and development activities and innovations are supervised by a multidisciplinary scientific committee composed of PhDs, pharmacists, MDs and eminent orthopedic or cardiovascular surgeons. I.Ceram is the only company to offer non-absorbable porous alumina implants with the ability to release biomolecules in situ. These innovative implants allow bone replacement in the case of bone metastases, but especially in the case of bone infections, osteitis and chronic osteomyelitis. I.Ceram has achieved two world firsts, in 2015 for the implantation of a ceramic sternum in the case of a sternal tumor and in 2016 for the implantation of a ceramic sternum loaded with an antibiotic in the case of chronic osteomyelitis. I.Ceram has obtained from the USA the patentability of its porous ceramic sternal implant loaded with an active substance.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>IMAGINOSTICS</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Imaginostics is a longevity startup developing medical imaging technology for quantifying brain abnormalities. Our magnetic resonance imaging (MRI) based technology overcomes the qualitative limitations of gadolinium perfusion mapping. We have finished our preclinical studies and are running a pivotal clinical study starting this Fall at Brigham and Women’s Hospital in Boston. The study will test the ability for early detection of dementia in patients with mild cognitive impairment. The second aim is to test the ability to quantify vascular abnormality in vascular dementia. In all, 96 subjects will be imaged twice for comparison to state-of-the-art imaging biomarkers, and further comparisons will be made to blood-based biomarkers and cognitive scores. Our technology is compatible with iron-oxide for contrast, which we believe is safer than toxic gadolinium-based contrast agents. Our technology is scalable because it is a readily deployable software that is compatible with existing MRI scanners and hardware. A single scan generates quantitative maps of vascular microstructure, function, and leakage. Other technologies can only measure these metrics qualitatively and are limited to large group research studies for statistical significance. Consequently, only gross abnormalities are picked-up by visual inspection of parametric perfusion maps by clinical radiologists. Imaginostics seeks to change the paradigm by delivering quantitative metrics for single patient precision medicine. We are working to provide clinicians with the tools needed for a robust and physiologically meaningful assessment of brain health. These tools support early preventative diagnostics, stratification of patient populations in drug development, assessment of drug efficacy, and companion diagnostics.</td>
</tr>
</tbody>
</table>

---

https://www.iceram.fr/

https://imaginosotics.com/
QUANTUM SURGICAL
Quantum Surgical is an innovative medical robotics company which has developed a new category of interventional oncology robots, called Epione® new standards in cancer treatment by enabling more targeted and less invasive treatments.
Epione® is designed to standardize interventional oncology procedures by combining image-guided navigation, planning and image fusion software advanced robotic assistance and tumor ablation confirmation into one solution. The platform allows physicians to overcome current challenges and expand capabilities all while allowing the freedom to use existing tools.
Epione® architecture system enables you to use any ablation system or modality (RF, MW, Cryo, IRE) to perform effective tumor ablations.
Quantum Surgical was founded in 2017 and is headquartered in Montpellier, France. For more information, please visit Quantum Surgical website and follow the company on LinkedIn and Twitter.

REMEDEE LABS
Based on 10 years of pre-clinical and clinical research, Remedee Labs has designed and developed the first endorphin stimulator for personal use. Building on the experience of its clinical partners, the company now uses its unique technology to offer the first patient-centered digital service for chronic pain management, working alongside medical practitioners.
Remedee Labs technology, embedded in the first endorphin stimulator wristband, stimulates the nerves’ endings at the wrist during 30-minute sessions. In response to this painless nerves' stimulation, the brain releases intracerebral endorphins recognized as the body's highly effective natural pain killer in a safe, fast and simple way.
Since chronic pain requires a comprehensive approach tailored to individual needs, Remedee Labs is an holistic experience that combines innovative technology, human coaching and digital services (education, peer support, self-monitoring). Placing the patient at the center of the treatment, it aims at a sustainable improvement of his/her quality of life.
Remedee Labs’ initial focus is Fibromyalgia, a debilitating chronic condition notably characterized by chronic pain, sleep disorders, anxiety and depression and translating into a very altered quality of life. In May 2022 FDA has granted Remedee Labs with the Breakthrough Device Designation for fibromyalgia patients based on its initial real-world evidence results, showing a clinically significant improvement in their quality of life (FIQ) and an improvement in their sleep quality (PSQI).
In addition, Remedee Labs is expanding its range of services to address other chronic pain conditions and has started several trials in endometriosis, osteoarthritis, migraines and cancer pain.

VELOCE CORP (SMARTTAB)
SmartTab is developing an advanced platform of ingestible capsules for oral drug delivery of biologics and targeted medications. We’re on a mission to provide novel administration routes and effective therapies that improve patient lives.
Robeauté is a MedTech start-up based in Paris, France, developing a microrobot for the brain, smaller than a grain of rice. More than one billion people worldwide are affected by neurological pathologies and physicians require local solutions to better understand and treat such disease. Though great effort is being put into developing innovative, local solutions, most therapies lack a way of being efficiently delivered to target locations within the brain parenchyma. The Blood Brain Barrier limits the entry of therapeutics and current neurosurgical tools are not suited to follow optimal curved routes, access target points at the proper chosen angle or reach multiple locations. Robeauté’s microrobot, with its modular and connected structure, is designed to navigate the brain’s extra-cellular-matrix, non-linearly along 3D routes, to deliver and carry different cargo such as sensors, therapeutics and tools -locally and potentially multisite, while collecting anatomically-precise, patient-specific data in real-time. The data collected will enable us to better understand the brain and the onset and spread of severe pathologies that remain without treatment today. It will allow us to design and perform new therapies and interventions, with fewer or no side effects, minimal invasiveness and more efficacy. The solution is being developed and tested with a prominent team of neurosurgeons and neuro-specialists in the US and in Europe, in order to bring to market a product that empowers the surgeon and allows them to intervene anywhere in the brain, with all the information and tools they may need, to cure the patient. With guidance from regulatory specialists and the medical board, the experienced team has designed a staged development plan to provide increased value over achievable milestones. At Robeauté we like to imagine a world where people can be cured from brain disease and where a microrobot would tend to a pathological brain, like a caring gardener - dialoguing, weeding, pruning, stimulating neurogenesis and adding therapeutics, when needed.

The Titan SGS® is a sterile, single-patient-use instrument used for resecting and stapling the stomach during laparoscopic and open surgical procedures. The entire stomach tissue is placed into the Titan SGS® allowing visualization of the full staple cut line in a single plane. Titan SGS® fires a single cartridge, completing the stapling in approximately 55 seconds. The resulting tubular surgical sleeve anatomy is a consistent shape that is free of kinks, twists, or spirals.

Innovation:
The Titan SGS® stapler is designed to help achieve more consistent and symmetrical sleeve pouch anatomy, setting patients up for the best possible outcomes. The Titan SGS® 23cm continuous staple line enables surgeons to plan and place staples in one firing, minimizing variations often associated with the current use of multiple overlapping short-cartridge staple firings. Bariatric surgeons are seeing benefits delivered to patients from the anatomy-based approach of Titan SGS® surgical stapler technology. Since the first use in gastric sleeve surgery on August 24, 2021, the Titan SGS® has now been used in over 4,000 clinical cases and efficacy data continues to build. Surgeons who have used the Titan SGS® in sleeve gastrectomy are reporting less operative time and less post-op patient nausea. Surgeons using Titan SGS® are also describing consistent and repeatable sleeve pouch creation. We believe that with improved outcomes, surgery will become the preferred treatment modality for both patients and referring physicians.
### ABYS MEDICAL

Abys Medical streamlines the surgical continuum of care with the vision of a game changer. The concept is Surgery 4.0, a holistic solution sublimating metaverse technologies to answer workflow issues from preoperative decision-making to surgery realization.

[https://abys-medical.com](https://abys-medical.com)

### AKILI INTERACTIVE

Akili is pioneering the development of cognitive treatments through game-changing technologies. Our approach of leveraging technologies designed to directly target the brain establishes a new category of medicine – medicine that is validated through clinical trials like a drug or medical device, but experienced like entertainment. Akili’s platform is powered by proprietary therapeutic engines designed to target cognitive impairment at its source in the brain, informed by decades of research and validated through rigorous clinical programs. Driven by Akili’s belief that effective medicine can also be fun and engaging, Akili’s products are delivered through captivating action video game experiences.

[https://www.akiliinteractive.com/](https://www.akiliinteractive.com/)

### BLOQCUBE

Bloqcube® Inc. Piscataway NJ is an innovative, unified, clinical trials management and financial software company focused on accelerating clinical trials at Lifescience firms. Its multiple modules (eConsent/eTMF/CTMS/EDC/Kit SCM/Financial module etc.) are integrated into a unified iPad, Cloud and Blockchain platform. The pain points of data integrity, lack of Real time data, vulnerability to Ransomware attacks, and payment inefficiencies are its focus. Its fully decentralized software is well suited for Hybrid or Decentralized trials and is compliant with Part 11 guidelines. Led by Rama K Rao - who spent 28 years in the Pharma industry (Lilly/Novartis) in multiple roles globally - it has a strong team of Clinical domain advisors for execution efficiencies. It is Smart, Secure and Speedy.

[https://bloqcube.com/](https://bloqcube.com/)
CARDIOSIGNAL
CardioSignal offers a groundbreaking motion sensor technology for heart disease detection to battle the costliest and deadliest chronic disease globally. This gyrocardiography-based technology can be considered as the most significant innovation in non-invasive heart function assessment in 50 years. CardioSignal is based on over a decade of academic research and algorithm development. The patented and published technology can be applied to a variety of devices and wearables but most importantly it can be run on billions of smartphones globally. The disruption of this medical device technology comes from the capability to measure heart motion from the chest and from the signal create digital biomarkers for several common and severe heart diseases such as heart failure, atrial fibrillation, coronary artery disease, aortic stenosis, and elevated pulmonary artery pressure. When applied on smartphones no additional hardware is needed, the measurement takes one minute, and the results are then immediate. Our platform offers a unique, scalable, accessible, and low-cost solution for remote patient monitoring and virtual care models, as well as a significant tool for standard healthcare. It is also the first truly scalable detection tool for under-served populations and patients in remote locations. CardioSignal enabled digital biomarkers will replace standard methods, such as use of blood biomarkers, improve health equity, and enhance early detection and monitoring of heart diseases. As a conclusion, we are offering a high impact digital health solution that will transform cardiovascular care.

https://cardiosignal.com/

FIFTH EYE
Fifth Eye Inc. is an Ann Arbor, Michigan-based company that develops and markets intuitive, real-time clinical analytics based on physiologic waveforms to improve outcomes and reduce costs. Fifth Eye’s FDA-cleared medical device software, the AHI SystemTM, provides hospital clinicians with unique, real-time information to facilitate early awareness of potentially serious emerging problems – ahead of vital signs – in adult patients throughout the hospital. Today, the standard in patient surveillance for life-threatening conditions is vital sign monitoring. But vital sign-based surveillance identifies patients whose compensatory mechanisms are already failing. So vital signs are a «lagging indicator» of these underlying problems - even with continuous hemodynamic monitoring in the ICU.

Fifth Eye’s founders leveraged machine learning to develop an analytic that was able to continuously monitor and identify patients who were hemodynamically unstable by detecting subtle changes in the waveform of a single, readily accessible source - continuous ECG Lead II signals (bedside, telemetry or remote). Subsequently, they developed a second analytic that could continuously predict a patient’s risk for an episode of hemodynamic instability – 48 minutes ahead of vital signs in the ICU and hours more in lower acuity settings.

The AHI System has been designed to provide clinicians “at-a-glance” awareness of the evolving hemodynamic trajectory of all monitored patients simultaneously. And to keep clinicians connected wherever they are in the hospital, they can access this information anytime on any web-enabled browser including mobile devices or a computer.

The AHI System has been deployed in pilots in multiple hospitals in the USA.

https://fiftheye.com/
MEDEXPRIM

Medexprim is the European company developing multi-centric Data lakes by disease based on RWD to solve the complex equation for personalized medicine: 1 patient, 1 condition, 1 treatment. We collect, curates, enriches, links and de-identifies patient centric data directly from European hospitals to provide Biopharmaceuticals with multiomics and contextualized regulatory grade data sets for retrospective and prospective studies.

Our medical data includes Medical Imaging, Clinical History and comorbidities, Treatment History, Genomics, Electronic Medical Record, Digital Pathology.

Our holistic expertise of data aims to provide longitudinal multicentric virtual cohorts with the more advanced tools to enhance precision medicine and patient stratification, diseases subtypes and progression monitoring to accelerate innovation for patients.

As a trusted third party between hospitals and industrials, we support Real-World Data projects and accelerate private / public partnerships for both prospective and retrospective studies.

Medexprim strategy is to create 10 European Data Lakes by 2025:
- 6 in Oncology
- 2 in Cardiology
- 2 in Neurology

We ambition to get Europe & USA closer in building transatlantic Data Lake on a unique Data Model together with a Bostonian expert of Multiomic data expert in oncology across USA: Concert AI

Our network of 30 Hospitals across Europe has been involved in 3 structural research projects led by the European Commission and coordinated by Medexprim.
**MINDMICS**

MindMics is the GPS of health and wellness: providing actionable biometric data to anyone, anywhere through proprietary in-earbud technology and our scalable cloud platform. MindMics has invented and patented a breakthrough technology (in-ear infrasonic hemodynography) for wireless earbuds that is using sound below the audible range, which when coupled with MindMics’ cloud-based analytics software, can power the next generation of health and wellness technology platforms. MindMics’s implementation of medical-grade technology to track health data using earbuds, a product easily accessible to consumers, has opened up the global market for real-time, user-based control over individual health outcomes with accurate feedback loops.

We are currently preparing to launch our first product, real-time biofeedback based on heart rate and heart rate variability enabled through our technology integrated into fully functional earbuds, with an app that coaches people to perform breathing exercises that help harness stress.

In the long term, we are planning to continue expanding our indications to monitor the entire cardiovascular system and to impact cardiac health to create a world where heart failure will no longer be the #1 killer.

**OCAMZ RAZOR**

OccamzRazor applies data science and machine learning to problems across pharmaceutical discovery and development. Our multidisciplinary team of biologists, artificial intelligence researchers, bioinformaticists, and data scientists are experts in developing practical solutions to meaningful problems which we define in close collaboration with our partners. Using proprietary algorithms we are able to drastically reduce the amount of time and cost required to solve the most pressing challenges in healthcare such as patient stratification, biomarker discovery, and target discovery. With an emphasis placed on custom-tailoring solutions for partners, OccamzRazor is able to think beyond the classic problems in pharmaceutical development and serve smaller, more niche teams across the industry that may not have historically explored data science and machine learning strategies in the past.

Founded in 2016 at Stanford University, OccamzRazor is now financially backed by some of the early pioneers in machine learning. OccamzRazor has been featured in WIRED magazine and MIT technology review, and won the most innovative startup prize at the CNS Summit in 2021.
PENTAVERE

Pentavere is an artificial intelligence (AI) digital health company that has developed a breakthrough, proprietary AI engine called DARWEN™ that dramatically accelerates the discovery of insights buried in vast amounts of clinical text data. DARWEN™ AI rapidly discovers, catalogs, organizes, and analyzes all types of clinical information, including electronic health records, physician notes, pathology reports, physician transcriptions and many other sources. Pentavere’s unique and scalable AI technology has proven real-world use cases with the world’s largest pharmaceutical companies, and industry leading results that have been validated and published in prestigious high-impact publications. With speed, accuracy, and unparalleled cost-savings, DARWEN™ AI unlocks lifesaving insights from millions of clinical data points buried within clinical text to power breakthrough health solutions.

“What Pentavere has achieved around data enrichment and curation, will have lasting and true benefit paving the way for true open science in our country.”
Dvorah Richler, Director Personalized Healthcare, Roche

“We are thrilled to have the opportunity to collaborate with Pentavere to leverage their AI technology within the field of rare diseases.”
Rute Fernandes, General Manager, Takeda

“Companies like Pentavere will bring healthcare into the 21st century.”
Dr. Nigel Hughes, Scientific Director, Janssen

SEQ ONE GENOMICS

SeqOne aims to make sophisticated genomic tests as quick and easy to perform as a blood test. Making genomic tests accessible is essential to implementing personalized medicine that customizes treatments to each patient’s disease, guided to a large extent by the patient’s unique genomic profile. Personalized medicine is rapidly becoming a mainstay in medicine because of its effectiveness in addressing cancer and other chronic diseases that account for most disease-related deaths and that don’t respond well to traditional medicine.

SeqOne’s has developed genomic analysis software specifically designed for the clinical routine environments where patients are treated. The software has been created with two objectives in mind; improving the efficiency of labs performing genomic analysis, while supporting a full range of tests to ensure that labs can address all the genomic testing requirements the medical community may require them to perform. To achieve these objectives, we rely heavily on big data and machine learning to identify relevant mutations, determine their impact on the patient and select the best course of treatment for each patient.

Today SeqOne’s solution is used by dozens of private and public sector labs to deliver genomic analysis in both oncology and inherited diseases, supporting the full range of genomic data from small panels to whole genomes. We continually develop new applications, often in partnership with leading medical researchers to reflect the most recent medical discoveries so that patients can always benefit from the best standard of care.
<table>
<thead>
<tr>
<th>SYNSIGHT</th>
<th>WE FIGHT</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SYNSIGHT</strong></td>
<td><strong>WE FIGHT</strong></td>
</tr>
<tr>
<td>Synsight is an AI-enhanced biotech focused on accelerating the discovery and development of a new class of small molecule drugs targeting RNA (Ribonucleic Acid). It specializes in targeting RNA-protein interactions to unlock new treatments for patients in oncology or those living with neurodegenerative disorders, among other unsolved pathologies.</td>
<td>Created in 2017, Wefight specializes in the digital health sector. Working alongside the top 10 pharmaceutical companies across the world, Wefight has created an eco-system of patient-centric products and services. The company’s first solution is Vik Companion, an application for patients living with cancer and chronic diseases. Gathering a community of over 500k patients in 15 countries and covering 18 pathologies, Vik empowers patients with medically validated content and provides them with resources to take action and shorten their time spent in clinical inertia. By identifying at-risk patients, Wefight’s objective is to drive behavioral health change by encouraging patients to visit the right practitioner at the right time according to their condition and its severity.</td>
</tr>
<tr>
<td>Powered by deep learning AI models followed by wet lab testing, Synsight is one of the first data-centric drug discovery companies equipped to analyze potential drug candidates from directly inside the cell. The robustness of this biological data approach, by measuring RNA-protein interactions, enables Synsight to select the best drug candidate ahead of most drug timelines.</td>
<td>Founded in 2013 and privately held, Synsight operates a joint lab with the University Evry Paris-Saclay (SABNP) and is a member of Genopole biocluster. The company employs eleven staff.</td>
</tr>
<tr>
<td>The Synsight’s cellular biology is improved by a proprietary and patented cell-based assay called MTbench. This is the only reliable and scalable technology for assessing the drug-RNA interaction inside of the cell. This increases the precision of the results in comparison to other methods. Using the MT bench technology, Synsight can qualify and quantify interactions directly inside the cell. The technology is amenable to high-throughput and broad applications, as evidenced in Synsight’s current projects within the fields of oncology, neurodegenerative and infectious diseases. The MTbench technology is the ‘missing link’ between target-based and phenotypic drug discovery.</td>
<td>Wefight has created an eco-system of patient-centric products and services. Its first solution is Vik Companion, an application for patients living with cancer and chronic diseases. Gathering a community of over 500k patients in 15 countries and covering 18 pathologies, Vik empowers patients with medically validated content and provides them with resources to take action and shorten their time spent in clinical inertia. By identifying at-risk patients, Wefight’s objective is to drive behavioral health change by encouraging patients to visit the right practitioner at the right time according to their condition and its severity.</td>
</tr>
</tbody>
</table>

**Links:**
- [Synsight](https://synsight.net/)
- [Wefight](https://wefight.co/en-US)
BRAINTALE

BrainTale transforms brain care by offering the first objective, reliable and non-invasive brain measures and assessment used in medical practice, hospitals and clinical development.

Spin-off from Paris Greater Hospitals, BrainTale is a medtech specialist in white matter, a long-underestimated area of interest in neurosciences. The company offers a platform of proprietary digital biomarkers, which can be employed in daily practice. Biomarkers are derived from magnetic resonance imaging, non-invasive measurements providing sensitive and reliable assessments of white matter alterations. Supporting clinical decision-making, these data are decisive for neurology and intensive care management using clinically validated predictive solutions.

BrainTale allows the identification of patients at risk, early diagnosis, follow-up of disease progression and effectiveness of treatments in neurology, in particular for demyelinating diseases (such as multiple sclerosis), neurodegenerative diseases (such as Alzheimer’s disease) or trauma brain injury.

CREAPHARM

Partnering with CREAPHARM, Pharma & Biotechs benefit from expert support from the preclinical/clinical development to the market launch: Biostorage, Clinical supply management and Commercial packaging

Contract Packaging & Logistics Organization

BIOSTORAGE
Securing Biobanking of your precious biological samples
- Biospecimen Kit Assembly
- Biospecimen Logistics with adapted & temperature-controlled transport solutions
- Biological sample storage at -196°C, -80°C, -20°C and +2°C/+8°C and ambient
- Training, consulting and audits by experts in biobanking

CLINICAL SUPPLY MANAGEMENT
Managing your Clinical Trial Material with agility
- Sourcing
- Clinical packaging/labeling of IMPs/IPs and Blinding
- Worldwide logistics and cold chain management
- EU QP-Release

COMMERCIAL PACKAGING
Meeting your packing and repacking challenges
- Design conception & packaging development
- Innovative industrial solutions implementation
- Blistering, filling, packing & repacking operations
- Quality services & support: batch release, serialization
DATEXIM

DATEXIM is an innovative company with a goal to empower pathologists to achieve exceptional clinical results, making it possible to improve early diagnosis of cervical cancer.

To achieve this goal, Datexim developed a groundbreaking technology called CytoProcessor, the first artificial intelligence-powered “CE certified” digital cytology screening system.

CytoProcessor analyzes images uploaded from scans of pap smear slides, identifies abnormal cells on the digitized slides and display them in a table sorted by relevance to improve diagnosis. Pathologist and cytotechnicians only need a standard web browser thanks to an architecture designed for remote diagnosis solving lack of local medical resources everywhere in the world. With CytoProcessor microscope quickly seems a memory of old times. This solution is used for clinical routine in private labs in Europe.

Faster screening, improved accuracy with less missed cases, increased reliability, greater productivity are benefits noticed every day by CytoProcessor’s users.

---

HACK YOUR CARE

Hack Your Care is the first platform to accelerate the connection and follow-up between innovative health projects and field healthcare professionals (from companies, institutions, health facilities).

Thanks to precise algorithmic profiling of healthcare professionals and projects in Health, Hack Your Care is able to provide in record time the field expert you need for a specific moment of your project. Build, test, communicate, investigate, commercialize, or advise, our mission is to provide the healthcare professional(s) who will adhere efficiently to your project, the success factor in healthcare innovation.

Founded in December 2021 by Dr. Solène Vo Quang Costantini, French surgeon and researcher, the start-up has already demonstrated its interest in France with the first growing community of over 600 healthcare professionals interested in innovation. Today Hack Your Care enters the American market with a team based in the USA and in France and first American users.

You want to be part of this innovative method, become a partner and join us on our Stand!
Nervosave is an early-stage Company incorporated in France with a focus on treating peripheral nerve diseases. The company plans to incorporate a subsidiary in the United States with an initial headquarters in White Plains early 2023.

Founded by Nicolas Tricaud, PhD, an internationally renowned and European Research Council laureate neuroscientist from France, the company has attracted highly seasoned directors and scientific advisors over two continents. The company plans to build a highly talented team, starting with a U.S.-based CEO.

Nervosave’s lead program, NVO-101, is a late-stage preclinical gene therapy program aimed at providing treatment for Charcot-Marie-Tooth disease type 1A ("CMT1A"). CMT1A is an inherited disabling neurological disorder that affects the peripheral nerves, leading to muscle wasting at limb extremities. It is the most common neuromuscular pathology, representing 70% of all hereditary peripheral neuropathies and over 37,000 patients in the United States and Europe. There is no approved treatment today.

Pre-clinical work has been completed, establishing efficacy and safety of NVO-101 in rodent models of the disease and in non-diseased monkeys. Successful pre-IND meeting with the FDA occurred in March 2022, with the aim of an accelerated approval path for commercialization as early as 2025.

The Company intends to perform a Phase I/II POC trial in North America within two years, after which the program will be out licensed to the industrial partner determined at that time to be best positioned to bring the program forward to successful launch.
Thank you to our sponsors that support the broader development of early-innovative medical technologies through their implication in the Prix Galien Startup
We’re a proud sponsor of the 2022 Prix Galien USA Forum and a proud financial partner of life science innovators.

YOUR growth | OUR support

Explore more at firstrepublic.com/lifescience

Member FDIC and Equal Housing Lender ™
BUSINESS FRANCE

We are deeply indebted to the following individuals who have devoted their enthusiasm and support to ensure the success of the Prix Galien Startup.

FRÉDÉRIC ROSSI
VP, Executive Director,
Business France North America

Jerome Revoile
Healthcare & Life Sciences
Managing Director, North America

Thibault Renac
Healthcare Trade Advisor
Prix Galien Startup Operations Manager

Julien Vermersch
Healthcare Trade Advisor
Prix Galien Startup Operations Manager

BUSINESS FRANCE, A GOVERNMENTAL SERVICE AGENCY TO PROMOTE BUSINESS IMAGE AND ATTRACTIVENESS OF FRANCE AND FRENCH COMPANIES IN THE WORLD

INVEST
ATTRACTING AND ENSURING THE SUCCESS OF FOREIGN INVESTMENT PROJECTS IN FRANCE AND HELP COMPANIES DOING BUSINESS IN FRANCE.

1,500 COLLABORATORS WORLDWIDE

EXPORT
CREATING BUSINESS OPPORTUNITIES FOR SMES AND MID-SIZE COMPANIES ABROAD.

TYPE OF ACTIONS
WE PROVIDE SUPPORT

IMPLEMENTATION (FIND A SPACE, RECRUITMENT, HELP FOR GRANT ELIGIBILITY...)

ADVICE ON ALL TYPES OF R&D COLLABORATIONS

CONDUCT STUDY ABOUT THE ELIGIBLE SUPPORT

EXPANSION.

INTRODUCTION TO KEY STAKEHOLDERS OF THE LOCAL ECOSYSTEM

IDENTIFICATION OF PARTNERS AND TALENTS

CONTACT : GALIENGBUSINESSFRANCE.FR
French Healthcare is an innovative public-private initiative aimed at bringing together all the players in the French healthcare ecosystem (businesses, researchers, healthcare professionals, key public stakeholders, etc.) to jointly promote their activities, expertise, technologies and innovations internationally. It helps to trigger a collective approach dynamic that stimulates international cooperation in the field of health and to promote the vision that health, a vector of social progress, must be improved for everyone everywhere in the world. This initiative is supported by the Ministry for Europe and Foreign Affairs, the French Healthcare Association and Business France.

Choose France is a registered trademark of the French government that promotes France’s economic attractiveness internationally.

Business France is the national agency supporting the international development of the French economy, responsible for fostering export growth by French businesses, as well as promoting and facilitating international investment in France. It promotes France’s companies, business image and nationwide attractiveness as an investment location, and also runs the VIE international internship program.

Business France has 1,500 personnel, both in France and in 55 countries throughout the world, who work with a network of partners. Since January 2019, as part of the reform of the state support system for exports, Business France has given private partners responsibility for supporting French SMEs and mid-size companies in the following markets: Belgium, Hungary, Morocco, Norway, the Philippines and Singapore.